Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has been assigned an average rating of “Hold” from the twenty analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and five have assigned a buy recommendation to the company. […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have received a consensus rating of “Hold” from the twenty brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have assigned a buy rating […]
Fate Therapeutics (NASDAQ:FATE – Get Free Report)‘s stock had its “neutral” rating reissued by equities research analysts at Wedbush in a note issued to investors on Thursday, RTT News reports. They presently have a $3.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $6.00. Wedbush’s target price would suggest […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been assigned a consensus recommendation of “Hold” from the nineteen ratings firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) was the target of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 13,800,000 shares, a drop of 7.4% from the September 30th total of 14,900,000 shares. Currently, 14.9% of the company’s shares are sold short. […]